Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOM-3: Dose Escalation in Rectal Cancer
NCT05241574Phase 2Unknown
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Aug 2021
- Primary completion
- Oct 2023
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, oxaliplatin in rectal cancer, sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Status: unknown.
02
Drugs
fluorouracilfolinic acidoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05241574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241574.